Recurrent reversible cerebral edema after long term immunosuppression with tacrolimus.
Reinohs
Manuela
M
Straube
Torsten
T
Baum
Petra
P
Berrouschot
Jörg
J
Wagner
Armin
A
D001921:Brain / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D001929:Brain Edema / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D003128:Coma / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D003244:Consciousness Disorders / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D003389:Cranial Nerve Diseases / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D004334:Drug Administration Schedule; D005073:Evoked Potentials, Somatosensory / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D009498:Neurotoxins / Q000009:adverse effects* / Q000627:therapeutic use; D011782:Quadriplegia / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology; D012008:Recurrence; D012640:Seizures / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D007166:Immunosuppressive Agents; D009498:Neurotoxins; D016559:Tacrolimus